Tiantian Ma1,2,3,4, Zhikai Yang1,2,3,4, Shaomei Li5, Huaying Pei5, Jinghong Zhao6, Yi Li6, Zibo Xiong7, Yumei Liao7, Zhanzheng Zhao8, Jing Xiao8, Ying Li9, Qiongzhen Lin9, Zhaoxia Zheng10, Liping Duan10, Gang Fu11, Shanshan Guo11, Wenbo Hu12, Yulin Li12, Fuyun Sun13, Nan Zhao13, Qin Wang14, Tianrong Ji14, Beiru Zhang15, Rui Yu15, Li Hao16, Guiling Liu16, Li Zuo17, Huiping Zhao17, Caili Wang18, Lirong Deng18, Hongyu Chen19, Li Li19, Yulan Shen20, Yong Zhang20, Lihua Wang21, Yan Yan21, Zhigang Ma22, Yingping Li22, Xianchao Zhang23, Xuejian Wang23, Yirong Liu24, Xinying Gao24, Zhonggao Xu25, Li Zhang25, Shutong Du26, Cui Zhao26, Xiaoli Chen27, Hongyi Li27, Yingli Yue28, Shanshan Chen28, Yingchun Ma29, Yuanyuan Wei29, Jingwei Zhou30, Jie Lv30, Yingdong Zheng31, Sainan Zhu32, Minghui Zhao1,2,3,4, Jie Dong1,2,3,4. 1. Renal Division, Department of Medicine, 26447Peking University First Hospital, Beijing, China. 2. Institute of Nephrology, 26447Peking University, Beijing, China. 3. Key Laboratory of Renal Disease, 12525Ministry of Health, Beijing, China. 4. Key Laboratory of Renal Disease, Ministry of Education, Beijing, China. 5. Renal Division, Department of Medicine, The Second Hospital of Hebei Medical University, Hebei, China. 6. Renal Division, Department of Medicine, Xinqiao Hospital of Army Medical University, Chongqing, China. 7. Renal Division, Department of Medicine, Peking University Shenzhen Hospital, Guangdong, China. 8. Renal Division, Department of Medicine, The First Affiliated Hospital of Zhengzhou University, Henan, China. 9. Renal Division, Department of Medicine, The Third Hospital of Hebei Medical University, Hebei, China. 10. Renal Division, Department of Medicine, Handan Central Hospital, Hebei, China. 11. Renal Division, Department of Medicine, Peking Haidian Hospital, Beijing, China. 12. Renal Division, Department of Medicine, People's Hospital of Qinghai Province, Qinghai, China. 13. Renal Division, Department of Medicine, Cangzhou Central Hospital, Hebei, China. 14. Renal Division, Department of Medicine, 535069The Second Affiliated Hospital of Harbin Medical University, Heilongjiang, China. 15. Department of Nephrology, Shengjing Hospital of China Medical University, Liaoning, China. 16. Renal Division, Department of Medicine, The Second Hospital of Anhui Medical University, Anhui, China. 17. Renal Division, Department of Medicine, 71185Peking University People's Hospital, Beijing, China. 18. Renal Division, Department of Medicine, The First Affiliated Hospital of BaoTou Medical College, Neimenggu, China. 19. Renal Division, Department of Medicine, The People's Hospital of Chuxiong Yi Autonomous Prefecture, Yunnan, China. 20. Renal Division, Department of Medicine, Beijing Miyun District Hospital, Beijing, China. 21. Renal Division, Department of Medicine, The Second Hospital of Shanxi Medical University, Shanxi, China. 22. Renal Division, Department of Medicine, People's Hospital of Gansu, Gansu, China. 23. Renal Division, Department of Medicine, Pingdingshan First People's Hospital, Henan, China. 24. Renal Division, Department of Medicine, The First People's Hospital of Xining, Qinghai, China. 25. Renal Division, Department of Medicine, First Hospital of Jilin University, Jilin, China. 26. Renal Division, Department of Medicine, Cangzhou People's Hospital, Hebei, China. 27. Renal Division, Department of Medicine, Taiyuan Central Hospital, Shanxi, China. 28. Renal Division, Department of Medicine, People's Hospital of Langfang, Hebei, China. 29. Renal Division, Department of Medicine, China Rehabilitation Research Center, Beijing Boai Hospital, Beijing, China. 30. Renal Division, Department of Medicine, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China. 31. Department of Epidemiology and Biostatistics, School of Public Health, 12465Peking University, Beijing, China. 32. Department of Statistics, 26447Peking University First Hospital, Beijing, China.
Abstract
OBJECTIVES: The primary objective of the Peritoneal Dialysis Telemedicine-assisted Platform Cohort (PDTAP) Study is to explore potential predictors and their effects on patient survival, technique survival, and the occurrence of infectious and noninfectious complications. DESIGN: The PDTAP study is a national-level cohort study in China. A newly developed PD telemedicine application provided a unique and convenient way to collect multicenter, structured data across units. SETTING: The PDTAP study was underway in 27 hospitals from 14 provinces located at 7 geographical regions (northwest, northeast, north, central, southwest, southeast, and south) in China. PARTICIPANTS: Our study aims to enroll at least 7000 adult patients with end-stage renal disease receiving PD. METHODS: Approval has been obtained through the ethics committees of all hospitals. All participants signed the informed consent form after the center had received ethics board approval in accordance with the Declaration of Helsinki. MAIN OUTCOME MEASURES: Patient survival, technique survival, hospitalization, and the occurrence of infectious and noninfectious complications. CONCLUSIONS: The PDTAP study aims to explore potential predictors and their effects on patient survival, technique survival, and infectious and noninfectious complications using a newly developed PD telemedicine system to collect multicenter, structured data in real-world practice. Substantial and transformable findings in relation to PD practices were expected. This study also developed a national-level infrastructure for further collaboration and ancillary investigation.
OBJECTIVES: The primary objective of the Peritoneal Dialysis Telemedicine-assisted Platform Cohort (PDTAP) Study is to explore potential predictors and their effects on patient survival, technique survival, and the occurrence of infectious and noninfectious complications. DESIGN: The PDTAP study is a national-level cohort study in China. A newly developed PD telemedicine application provided a unique and convenient way to collect multicenter, structured data across units. SETTING: The PDTAP study was underway in 27 hospitals from 14 provinces located at 7 geographical regions (northwest, northeast, north, central, southwest, southeast, and south) in China. PARTICIPANTS: Our study aims to enroll at least 7000 adult patients with end-stage renal disease receiving PD. METHODS: Approval has been obtained through the ethics committees of all hospitals. All participants signed the informed consent form after the center had received ethics board approval in accordance with the Declaration of Helsinki. MAIN OUTCOME MEASURES: Patient survival, technique survival, hospitalization, and the occurrence of infectious and noninfectious complications. CONCLUSIONS: The PDTAP study aims to explore potential predictors and their effects on patient survival, technique survival, and infectious and noninfectious complications using a newly developed PD telemedicine system to collect multicenter, structured data in real-world practice. Substantial and transformable findings in relation to PD practices were expected. This study also developed a national-level infrastructure for further collaboration and ancillary investigation.